Please login to the form below

Not currently logged in

GSK under investigation in Poland for 'camouflaged bribes'

A regional manager and 11 doctors have been charged, according to a BBC report
GlaxoSmithKline GSK

GlaxoSmithKline (GSK) is facing a criminal investigation in Poland on allegations that company staff bribed doctors to prescribe drugs, according to the BBC.

A report due to air this evening on the UK network's Panorama programme - which featured interviews with a former GSK sales representative - will claim that company employees paid doctors to promote drugs such as its asthma therapy Seretide (fluticasone and salmeterol).

Whistleblower Jarek Wisniewiski, who worked as a sales rep for GSK in Poland for eight years but left the company in 2012, claims the money paid to doctors was ostensibly for medical training, but in reality was intended to boost sales.

Another unidentified employee said the company paid doctors to give presentations that never actually occurred, but did result in higher prescribing levels for its products. One of GSK's regional managers and 11 doctors have been charged by the prosecutor's office in Lodz, according to the BBC team, which says the offences occurred between 2010 and 2012.

GSK said in a statement that its own investigation into the matter "found evidence of inappropriate communication in contravention of GSK policy by a single employee" who has been "reprimanded and disciplined."

The news puts another dent in GSK's reputation as the company is still facing allegations of corrupt marketing practices in China, along with a number of other pharmaceutical companies. The company's own investigation into the Chinese situation - commissioned by lawfirm Ropes and Gray - has yet to deliver its findings.

Meanwhile, just a few days ago fresh corruption allegations surfaced centring on GSK's business practices in Iraq, with media reports claiming the company hired 16 Iraqi government doctors and pharmacists to act as sales representatives.

In 2012, GSK paid a massive $3bn settlement to the US government after pleading guilty to mis-promoting medicines, and since then has implemented a series of changes to try to reduce the risk of corruption, for example by doing away with sales targets for reps and using in-house doctors and scientists rather than external speakers to present on its products.

Article by
Phil Taylor

14th April 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...